Relapsed Diffuse Large B-cell Lymphoma (DLBCL) (DBCOND0078633)

Identifiers

Synonyms

Relapse Diffuse Large B Cell Lymphoma / Relapsed Diffuse Large B Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma / Relapsed, Diffuse Large B-cell Lymphoma / Relapsed Large B-cell Lymphoma / Diffuse Large B Cell Lymphoma Relapsed / Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Axicabtagene ciloleucel	A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma.	B-lymphocyte antigen CD19target
Epcoritamab	A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.	B-lymphocyte antigen CD20target T-cell surface glycoprotein CD3 epsilon chaintarget
Glofitamab	A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.	B-lymphocyte antigen CD20target T-cell surface glycoprotein CD3target
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target
Loncastuximab tesirine	An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.	B-lymphocyte antigen CD19target ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme
Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.	B-lymphocyte antigen CD19target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04836507	Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients	Cyclophosphamide Fludarabine	treatment	1 / 2	recruiting
NCT02658968	Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)	Lilotomab Lutetium Lu-177 Tetulomab tetraxetan Lu-177	treatment	1	completed
NCT04384484	Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Gemcitabine Loncastuximab tesirine Oxaliplatin Rituximab	treatment	3	recruiting
NCT05267054	Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab	Ociperlimab Rituximab Tislelizumab	treatment	1 / 2	active_not_recruiting
NCT03488251	PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma	Gemcitabine Oxaliplatin	treatment	2	terminated
NCT03305445	Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL	Ipilimumab Nivolumab	treatment	1	completed
NCT03688152	A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma	Parsaclisib Uzansertib	treatment	1	completed
NCT03287817	CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	AUTO3	treatment	1 / 2	completed
NCT04659434	Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL	Sintilimab	treatment	2	not_yet_recruiting
NCT05068440	Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib	Zanubrutinib	treatment	2	recruiting
NCT04833114	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)	Carboplatin Etoposide Ifosfamide Polatuzumab vedotin Rituximab	treatment	3	recruiting
NCT03136497	A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Ibrutinib Rituximab Venetoclax	treatment	1	active_not_recruiting
NCT04920617	DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Cyclophosphamide Maveropepimut-S Pembrolizumab	treatment	2	recruiting
NCT02348216	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma	Axicabtagene ciloleucel Bendamustine Carboplatin Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Fludarabine Gemcitabine Ifosfamide Levetiracetam Methylprednisolone Oxaliplatin Prednisone Rituximab Tocilizumab Vincristine	treatment	1 / 2	completed
NCT04572763	Copanlisib Plus Venetoclax in R/R DLBCL	Copanlisib Venetoclax	treatment	1 / 2	active_not_recruiting
NCT02077166	Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Ibrutinib Lenalidomide Rituximab	treatment	1 / 2	completed
NCT03422523	Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy	Atezolizumab Gemcitabine Oxaliplatin Rituximab	treatment	2	terminated
NCT05222438	Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant	Loncastuximab tesirine	treatment	2	withdrawn
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	Fimepinostat Rituximab Venetoclax	treatment	1	completed
NCT02570542	Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Carmustine Cytarabine Etoposide Melphalan Plerixafor	treatment	2	active_not_recruiting
NCT05836896	A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies	No drug interventions	treatment	1	recruiting
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT02142049	Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Ibrutinib Lenalidomide	treatment	1 / 2	completed
NCT06458439	Epcoritamab-CAR T Cells for Large B-cell Lymphomas	Epcoritamab	treatment	2	recruiting
NCT04792489	DALY II USA/ MB-CART2019.1 for DLBCL	Bendamustine Cyclophosphamide Fludarabine Zamtocabtagene autoleucel	treatment	2	recruiting